Skip to content
VuFind
  • Login
    • English
    • اللغة العربية
Advanced
  • Decision tree and model struct...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Save to List
  • Permanent link
Decision tree and model structure overview.

Decision tree and model structure overview.

<p><b><i>TNBC</i></b> triple-negative breast cancer; <b><i>ITT</i></b> intention-to-treat; <b><i>M</i></b> Markov model.</p>

Saved in:
Bibliographic Details
Main Author: Ping Chen (89712) (author)
Other Authors: Dan Qiao (72747) (author), Liping Xiao (1479571) (author), Guiya Deng (20978756) (author), Qing Yang (67856) (author), Rendi Tian (20978759) (author)
Published: 2025
Subjects:
Medicine
Biotechnology
Cancer
Science Policy
Infectious Diseases
year markov model
potential paradigm shift
negative breast cancer
model incorporated efficacy
adjusted life years
68 life years
developed using data
750 per qaly
sensitivity analyses indicated
qaly wtp threshold
us </ p
toripalimab plus nab
tnbc patients resulted
wtp threshold
sensitivity analyses
safety data
xlink ">
variable uncertainties
toripalimab suggest
toripalimab combined
torchlight study
tnbc within
survival utility
recurrent tnbc
qalys ),
line therapy
effective compared
effective advantage
derived costs
calculated icers
analysis suggests
advanced triple
advanced tnbc
additional 2
72 quality
Tags: Add Tag
No Tags, Be the first to tag this record!
  • Holdings
  • Description
  • Comments
  • Similar Items
  • Staff View

Similar Items

  • Base-case results.
    by: Ping Chen (89712)
    Published: (2025)
  • Model parameters: baseline values, ranges, and distributions for sensitivity analysis.
    by: Ping Chen (89712)
    Published: (2025)
  • Summary of the goodness of statistical fit of the KM curve in the TORCHLIGHT trial.
    by: Ping Chen (89712)
    Published: (2025)
  • Cost-effectiveness acceptability curve for comparisons among various treatment regimens.
    by: Ping Chen (89712)
    Published: (2025)
  • One-way sensitivity analysis tornado diagram of the incremental cost–effectiveness ratio (cost per quality-adjusted life-year) of toripalimab plus chemotherapy versus chemotherapy. cT, cost per cycle of toripalimab; uPfs, utility of subsequent free survival cycle; uPD, utility of progressive disease; cSt, cost of subsequent treatment per cycle after disease progression; cNab, cost per cycle of nab-paclitaxel; PPNe, probability of care in the PN group; cTcpa, utility of neutropenia per cycle; PTNNe, probability of care in the T+  N group; experiencing terminal cost cBs, carboplatin body surface area (m<sup>2</sup>); cN, cost per cycle of neutropenia; PTNLe, probability of experiencing leukopenia in the T +  N group; PPNLe, probability of experiencing leukopenia in the PN group; cCt, cost of CT scan; cTi, cost of tumor imaging; ucost, cost of leukopenia; uNe, cost of leukopenia; cL, cost of leukopenia; cC, cost of utility (1 mg); cG, cost of gemcitabine; cLt, cost of laboratory testing.
    by: Ping Chen (89712)
    Published: (2025)

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items
Cannot write session to /tmp/vufind_sessions/sess_9iiirn8s7c2ovsq43aujalltsa